GlassScriptPhysician profile
Salim K Durrani
NPI 1003105065
$2,877.88
in general payments reported to CMS, 2019-2025
24 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $387 · 2021: $647 · 2022: $662 · 2023: $200 · 2024: $325 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $773.12 | 2020-2024 | Proclaim |
| Amgen INC. | $284.80 | 2019-2022 | |
| Medtronic, INC. | $265.23 | 2021-2024 | Intellis Adaptivestim |
| Biodelivery Sciences International, INC. | $224.13 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $192.14 | 2019-2025 | Belbuca, Nucynta, Xtampza |
| Horizon Therapeutics Plc | $182.43 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $150.69 | 2019-2023 | Ztlido |
| Medtronic USA, INC. | $119.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $105.87 | 2019-2021 | |
| Epimed International, INC | $94.12 | 2021 | |
| Almatica Pharma LLC | $77.45 | 2021 | |
| Masimo Corporation | $72.31 | 2024 | Patient Safetynet System |
| Novartis Pharmaceuticals Corporation | $58.96 | 2019 | |
| Boston Scientific Corporation | $46.75 | 2025 | Intracept |
| Tersera Therapeutics LLC | $42.36 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $37.76 | 2025 | Qutenza |
| Amniox Medical, INC. | $23.91 | 2020 | |
| Zyla Life Sciences, INC. | $22.11 | 2020 | |
| Assertio Therapeutics, INC. | $21.25 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.55 | 2023 | Givlaari |
| Kowa Pharmaceuticals America, INC. | $17.46 | 2023 | Seglentis |
| Azurity Pharmaceuticals, INC. | $17.03 | 2024 | |
| Bioventus LLC | $16.60 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.85 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salim Durrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.